72 tracked 13F filers disclose a position in BLTE as of the latest SEC 13F filings, a combined $1.4B in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Darwin Global Management, Ltd. | $456.1M | 3.1M | ▲+1.0% Added · +30K sh | Q1 2026 | |
| 2 | Paradigm Biocapital Advisors LP | $177.7M | 1.1M | ▲New +1.1M sh | Q1 2026 | |
| 3 | UBS Group AG | $122.5M | 768K | ▲+497% Added · +640K sh | Q1 2026 | |
| 4 | RTW INVESTMENTS, LP | $110.2M | 715K | —Held | Q2 2026 | |
| 5 | MILLENNIUM MANAGEMENT LLC | $90.9M | 570K | ▲+2.0% Added · +11K sh | Q1 2026 | |
| 6 | Holocene Advisors, LP | $78.8M | 494K | ▲+488% Added · +410K sh | Q1 2026 | |
| 7 | EVENTIDE ASSET MANAGEMENT, LLC | $57.0M | 358K | ▼−6.6% Reduced · −25K sh | Q1 2026 | |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. | $48.5M | 304K | ▲+30% Added · +70K sh | Q1 2026 | |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | $44.9M | 282K | ▲New +282K sh | Q1 2026 | |
| 10 | MORGAN STANLEY | $32.1M | 201K | ▲+619% Added · +173K sh | Q1 2026 | |
| 11 | PERCEPTIVE ADVISORS LLC | $24.2M | 152K | ▼−63% Reduced · −262K sh | Q1 2026 | |
| 12 | Patient Square Capital LP | $16.9M | 110K | ▼−5.7% Reduced · −7K sh | Q2 2026 | |
| 13 | Duquesne Family Office LLC | $16.3M | 106K | —Held | Q2 2026 | |
| 14 | GOLDMAN SACHS GROUP INC | $16.8M | 106K | ▲+137% Added · +61K sh | Q1 2026 | |
| 15 | MPM BioImpact LLC | $14.0M | 88K | ▲+0.3% Added · +285 sh | Q1 2026 | |
| 16 | Affinity Asset Advisors, LLC | $10.4M | 65K | ▲+225% Added · +45K sh | Q1 2026 | |
| 17 | FRED ALGER MANAGEMENT, LLC | $10.0M | 63K | ▼−21% Reduced · −17K sh | Q1 2026 | |
| 18 | RENAISSANCE TECHNOLOGIES LLC | $8.3M | 52K | ▲New +52K sh | Q1 2026 | |
| 19 | Soleus Capital Management, L.P. | $7.8M | 51K | ▲Added Added · +51K sh | Q2 2026 | |
| 20 | PFM Health Sciences, LP | $5.4M | 35K | ▼−41% Reduced · −25K sh | Q2 2026 | |
| 21 | Longaeva Partners L.P. | $5.3M | 33K | ▲New +33K sh | Q1 2026 | |
| 22 | TD ASSET MANAGEMENT INC | $5.3M | 33K | ▲New +33K sh | Q1 2026 | |
| 23 | BNP PARIBAS FINANCIAL MARKETS | $5.2M | 33K | ▲13× Added · +30K sh | Q1 2026 | |
| 24 | Walleye Capital LLC | $4.9M | 32K | ▲New +32K sh | Q2 2026 | |
| 25 | ADAR1 Capital Management, LLC | $4.3M | 27K | ▼−33% Reduced · −13K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 20 funds opened a new position in BLTE and 16 added to an existing one, while 11 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| REVOLUTION MEDICINES INCRVMD | 41 funds | $3.4B |
| ELI LILLY & COLLY | 37 funds | $20.7B |
| META PLATFORMS INC-CLASS AMETA | 36 funds | $32.5B |
| AMAZON.COM INCAMZN | 35 funds | $51.4B |
| INSMED INCINSM | 35 funds | $5.0B |
| NVIDIA CORPNVDA | 34 funds | $109.5B |
| BROADCOM INCAVGO | 34 funds | $42.2B |
| ALPHABET INC-CL AGOOGL | 34 funds | $40.2B |
| GILEAD SCIENCES INCGILD | 34 funds | $7.3B |
| SANDISK CORPSNDK | 34 funds | $3.8B |
| CYTOKINETICS INCCYTK | 34 funds | $777.0M |
| XENON PHARMACEUTICALS INCXENE | 34 funds | $690.5M |
Ranked by how many of BLTE's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Aug 12, 2026 | Chuang Hao-Yuan | Chief Financial Officer, Director | Sell (S) | 144 | $26K |
| Aug 12, 2026 | Chuang Hao-Yuan | Chief Financial Officer, Director | Sell (S) | 223 | $40K |
| Aug 12, 2026 | Lin Yu-Hsin | Chief Executive Officer, Director | Sell (S) | 142 | $26K |
| Aug 12, 2026 | Lin Yu-Hsin | Chief Executive Officer, Director | Sell (S) | 223 | $40K |
| Jun 18, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell (S) | 96 | $14K |
| Jun 18, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell (S) | 4K | $542K |
| Jun 18, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell (S) | 5K | $707K |
| Jun 18, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell (S) | 1K | $175K |
| Jun 18, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell (S) | 96 | $14K |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell (S) | 2K | $283K |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell (S) | 784 | $108K |
| Jun 16, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell (S) | 3K | $438K |
Connected entities for BLTE
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/BLTE/capital-change-brief"
Use Arkolith's capital_change_brief for BLTE. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for BLTE. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.